-
1
-
-
0037418546
-
Management of the clinically inapparent adrenal mass ('incidentaloma')
-
Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass ('incidentaloma'). Ann Intern Med 2003;138:424-429.
-
(2003)
Ann Intern Med
, vol.138
, pp. 424-429
-
-
Grumbach, M.M.1
Biller, B.M.2
Braunstein, G.D.3
-
2
-
-
1942436088
-
The clinically inapparent adrenal mass: Update in diagnosis and management
-
Mansmann G, Lau J, Balk E, et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 2004;25:309-340.
-
(2004)
Endocr Rev
, vol.25
, pp. 309-340
-
-
Mansmann, G.1
Lau, J.2
Balk, E.3
-
3
-
-
0024513504
-
Pathologic features of prognostic significance in adrenocortical carcinoma
-
Weiss LM, Medeiros LJ, Vickery Jr AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989;13:202-206.
-
(1989)
Am J Surg Pathol
, vol.13
, pp. 202-206
-
-
Weiss, L.M.1
Medeiros, L.J.2
Vickery Jr., A.L.3
-
4
-
-
0034477224
-
Histopathological classification of adrenal tumours
-
Saeger W. Histopathological classification of adrenal tumours. Eur J Clin Invest 2000;30(Suppl 3):58-62.
-
(2000)
Eur J Clin Invest
, vol.30
, Issue.SUPPL. 3
, pp. 58-62
-
-
Saeger, W.1
-
5
-
-
34347354300
-
Recent advances in histopathology and immunohistochemistry of adre-nocortical carcinoma
-
Sasano H, Suzuki T, Moriya T. Recent advances in histopathology and immunohistochemistry of adre-nocortical carcinoma. Endocr Pathol 2006;17:345-354.
-
(2006)
Endocr Pathol
, vol.17
, pp. 345-354
-
-
Sasano, H.1
Suzuki, T.2
Moriya, T.3
-
6
-
-
0034651712
-
Adrenocortical carcinoma: Clinical and laboratory observations
-
Wajchenberg BL, Albergaria Pereira MA, Medonca BB, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000;88:711-736.
-
(2000)
Cancer
, vol.88
, pp. 711-736
-
-
Wajchenberg, B.L.1
Pereira Ma, A.2
Medonca, B.B.3
-
7
-
-
34249810952
-
Adrenocortical cancer: Pathophysiology and clinical management
-
Libe R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007;14:13-28.
-
(2007)
Endocr Relat Cancer
, vol.14
, pp. 13-28
-
-
Libe, R.1
Fratticci, A.2
Bertherat, J.3
-
8
-
-
17644399691
-
Management of patients with adrenal cancer: Recommendations of an international consensus conference
-
Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 2005;12:667-680.
-
(2005)
Endocr Relat Cancer
, vol.12
, pp. 667-680
-
-
De, S.1
Doherty, G.M.2
Gauger, P.G.3
-
9
-
-
33744952176
-
Clinical review: Adrenocortical carcinoma: Clinical update
-
Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006;91:2027-2037.
-
(2006)
J Clin Endocrinol Metab
, vol.91
, pp. 2027-2037
-
-
Allolio, B.1
Fassnacht, M.2
-
10
-
-
0036298023
-
Signaling pathways in adrenocortical cancer
-
Kirschner LS. Signaling pathways in adrenocortical cancer. Ann NY Acad Sci 2002;968:222-239.
-
(2002)
Ann NY Acad Sci
, vol.968
, pp. 222-239
-
-
Kirschner, L.S.1
-
11
-
-
2442532063
-
Adrenocortical cancer: Recent clinical and molecular advances
-
Sidhu S, Sywak M, Robinson B, et al. Adrenocortical cancer: recent clinical and molecular advances. Curr Opin Oncol 2004;16:13-18.
-
(2004)
Curr Opin Oncol
, vol.16
, pp. 13-18
-
-
Sidhu, S.1
Sywak, M.2
Robinson, B.3
-
12
-
-
27644431904
-
Molecular genetics of adrenocor-tical tumours, from familial to sporadic diseases
-
Libe R, Bertherat J. Molecular genetics of adrenocor-tical tumours, from familial to sporadic diseases. Eur J Endocrinol 2005;153:477-487.
-
(2005)
Eur J Endocrinol
, vol.153
, pp. 477-487
-
-
Libe, R.1
Bertherat, J.2
-
13
-
-
0020424709
-
Syn thesis, turnover, and down-regulation of epidermal growth factor receptors in human A431 epidermoid carcinoma cells and skin fibroblasts
-
Krupp MN, Connolly DT, Lane MD. Synthesis, turnover, and down-regulation of epidermal growth factor receptors in human A431 epidermoid carcinoma cells and skin fibroblasts. J Biol Chem 1982;257: 11489-11496.
-
(1982)
J Biol Chem
, vol.257
, pp. 11489-11496
-
-
Krupp, M.N.1
Connolly, D.T.2
Lane, M.D.3
-
14
-
-
0022600388
-
The neu oncogene encodes an epidermal growth factor receptor-related protein
-
Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319:226-230.
-
(1986)
Nature
, vol.319
, pp. 226-230
-
-
Bargmann, C.I.1
Hung, M.C.2
Weinberg, R.A.3
-
15
-
-
31544462308
-
Expression of epidermal growth factors and their receptors in the bronchial epithelium of subjects with chronic obstructive pulmonary disease
-
De Boer WI, Hau CM, van Schadewijk A, et al. Expression of epidermal growth factors and their receptors in the bronchial epithelium of subjects with chronic obstructive pulmonary disease. Am J Clin Pathol 2006;125:184-192.
-
(2006)
Am J Clin Pathol
, vol.125
, pp. 184-192
-
-
De Boer, W.I.1
Hau, C.M.2
Van Schadewijk, A.3
-
16
-
-
0030795612
-
The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions
-
Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997;410:83-86.
-
(1997)
FEBS Lett
, vol.410
, pp. 83-86
-
-
Alroy, I.1
Yarden, Y.2
-
17
-
-
0034773992
-
The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities
-
Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37(Suppl 4):S3-S8.
-
(2001)
Eur J Cancer
, vol.37
, Issue.SUPPL. 4
-
-
Yarden, Y.1
-
18
-
-
21344432989
-
Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetux-imab: An Acta Oncologica expert report
-
Nygren P, Sorbye H, Osterlund P, et al. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetux-imab: an Acta Oncologica expert report. Acta Oncol 2005;44:203-217.
-
(2005)
Acta Oncol
, vol.44
, pp. 203-217
-
-
Nygren, P.1
Sorbye, H.2
Osterlund, P.3
-
19
-
-
27144441838
-
The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: What's genetics got to do with it
-
Shelton JG, Steelman LS, Abrams SL, et al. The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it- Expert Opin Ther Targets 2005;9:1009-1030.
-
(2005)
Expert Opin Ther Targets
, vol.9
, pp. 1009-1030
-
-
Shelton, J.G.1
Steelman, L.S.2
Abrams, S.L.3
-
20
-
-
9144256014
-
Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer
-
Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004;15:28-32.
-
(2004)
Ann Oncol
, vol.15
, pp. 28-32
-
-
Selvaggi, G.1
Novello, S.2
Torri, V.3
-
21
-
-
0036164390
-
Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer
-
Tsutsui S, Ohno S, Murakami S, et al. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 2002;71:67-75.
-
(2002)
Breast Cancer Res Treat
, vol.71
, pp. 67-75
-
-
Tsutsui, S.1
Ohno, S.2
Murakami, S.3
-
22
-
-
3242720345
-
Cetuximab monotherapy and cetuximab plus irinotecan in irino-tecan-refractory metastatic colorectal cancer
-
Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irino-tecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
-
(2004)
N Engl J Med
, vol.351
, pp. 337-345
-
-
Cunningham, D.1
Humblet, Y.2
Siena, S.3
-
23
-
-
22044445517
-
Erlotinib in previously treated non-small-cell lung cancer
-
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
-
(2005)
N Engl J Med
, vol.353
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues Pereira, J.2
Ciuleanu, T.3
-
24
-
-
34249933404
-
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group
-
Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1960-1966
-
-
Moore, M.J.1
Goldstein, D.2
Hamm, J.3
-
25
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
-
26
-
-
2342624080
-
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
-
Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Janne, P.A.2
Lee, J.C.3
-
27
-
-
22044453790
-
Erlotinib in lung cancer-molecular and clinical predictors of outcome
-
Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144.
-
(2005)
N Engl J Med
, vol.353
, pp. 133-144
-
-
Tsao, M.S.1
Sakurada, A.2
Cutz, J.C.3
-
29
-
-
29144496089
-
Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy
-
Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy. Eur J Cancer 2006;42:17-23.
-
(2006)
Eur J Cancer
, vol.42
, pp. 17-23
-
-
Chan, S.K.1
Gullick, W.J.2
Hill, M.E.3
-
30
-
-
33846444010
-
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing
-
Sequist LV, Joshi VA, Janne PA, et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist 2007;12:90-98.
-
(2007)
Oncologist
, vol.12
, pp. 90-98
-
-
Sequist, L.V.1
Joshi, V.A.2
Janne, P.A.3
-
31
-
-
0030890465
-
Biological characteristics of adrenocortical carcinoma: A study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas
-
Edgren M, Eriksson B, Wilander E, et al. Biological characteristics of adrenocortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas. Anticancer Res 1997;17:1303-1309. (Pubitemid 27182456)
-
(1997)
Anticancer Research
, vol.17
, Issue.2 B
, pp. 1303-1309
-
-
Edgren, M.1
Eriksson, B.2
Wilander, E.3
Westlin, J.-E.4
Nilsson, S.5
Oberg, K.6
-
32
-
-
0025193837
-
Immunohisto-chemical expression of epidermal growth factor receptors in human adrenocortical carcinoma
-
Kamio T, Shigematsu K, Sou H, et al. Immunohisto-chemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum Pathol 1990;21:277-282.
-
(1990)
Hum Pathol
, vol.21
, pp. 277-282
-
-
Kamio, T.1
Shigematsu, K.2
Sou, H.3
-
33
-
-
0028512184
-
Transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor expression in normal and diseased human adrenal cortex by immunohisto-chemistry and in situ hybridization
-
Sasano H, Suzuki T, Shizawa S, et al. Transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor expression in normal and diseased human adrenal cortex by immunohisto-chemistry and in situ hybridization. Mod Pathol 1994; 7:741-746.
-
(1994)
Mod Pathol
, vol.7
, pp. 741-746
-
-
Sasano, H.1
Suzuki, T.2
Shizawa, S.3
-
34
-
-
66349120812
-
An analysis of potential surrogate markers of target-specific therapy in archival materials of adrenocortical carcinoma
-
Nakamura M, Miki Y, Akahira J, et al. An analysis of potential surrogate markers of target-specific therapy in archival materials of adrenocortical carcinoma. Endocr Pathol 2009;20:17-23.
-
(2009)
Endocr Pathol
, vol.20
, pp. 17-23
-
-
Nakamura, M.1
Miki, Y.2
Akahira, J.3
-
35
-
-
71149093992
-
Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma
-
Fenske W, Volker HU, Adam P, et al. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer 2009;16:919-928.
-
(2009)
Endocr Relat Cancer
, vol.16
, pp. 919-928
-
-
Fenske, W.1
Volker, H.U.2
Adam, P.3
-
36
-
-
72749100910
-
Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy
-
Ronchi CL, Sbiera S, Kraus L, et al. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr Relat Cancer 2009;16:907-918.
-
(2009)
Endocr Relat Cancer
, vol.16
, pp. 907-918
-
-
Ronchi, C.L.1
Sbiera, S.2
Kraus, L.3
-
37
-
-
66849087625
-
Osteopontin stimulates invasion of NCI-h295 cells but is not associated with survival in adrenocortical carcinoma
-
Weismann D, Briese J, Niemann J, et al. Osteopontin stimulates invasion of NCI-h295 cells but is not associated with survival in adrenocortical carcinoma. J Pathol 2009;218:232-240.
-
(2009)
J Pathol
, vol.218
, pp. 232-240
-
-
Weismann, D.1
Briese, J.2
Niemann, J.3
-
38
-
-
0029844506
-
The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer
-
Ioachim E, Kamina S, Athanassiadou S, et al. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer. Anticancer Res 1996;16:3141-3147.
-
(1996)
Anticancer Res
, vol.16
, pp. 3141-3147
-
-
Ioachim, E.1
Kamina, S.2
Athanassiadou, S.3
-
39
-
-
33751247325
-
Matrix metalloproteinase type 2 expression in malignant adrenocortical tumors: Diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas
-
Volante M, Sperone P, Bollito E, et al. Matrix metalloproteinase type 2 expression in malignant adrenocortical tumors: diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas. Mod Pathol 2006;19:1563-1569.
-
(2006)
Mod Pathol
, vol.19
, pp. 1563-1569
-
-
Volante, M.1
Sperone, P.2
Bollito, E.3
-
40
-
-
0034839753
-
Discerning malignancy in adrenocortical tumors: Are molecular markers useful
-
Wachenfeld C, Beuschlein F, Zwermann O, et al. Discerning malignancy in adrenocortical tumors: are molecular markers useful- Eur J Endocrinol 2001;145:335-341.
-
(2001)
Eur J Endocrinol
, vol.145
, pp. 335-341
-
-
Wachenfeld, C.1
Beuschlein, F.2
Zwermann, O.3
-
41
-
-
42649093507
-
The role of immunohistochemistry in histopathological diagnostics of clinically 'silent' incidentally detected adrenal masses
-
Babinska A, Sworczak K, Wisniewski P, et al. The role of immunohistochemistry in histopathological diagnostics of clinically 'silent' incidentally detected adrenal masses. Exp Clin Endocrinol Diabetes 2008;116:246-251.
-
(2008)
Exp Clin Endocrinol Diabetes
, vol.116
, pp. 246-251
-
-
Babinska, A.1
Sworczak, K.2
Wisniewski, P.3
-
42
-
-
33747404192
-
IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours
-
Schmitt A, Saremaslani P, Schmid S, et al. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours. Histopathology 2006;49:298-307.
-
(2006)
Histopathology
, vol.49
, pp. 298-307
-
-
Schmitt, A.1
Saremaslani, P.2
Schmid, S.3
-
43
-
-
0029838924
-
MHC class II expression-a new tool to assess dignity in adreno-cortical tumours
-
Marx C, Wolkersdorfer GW, Brown JW, et al. MHC class II expression-a new tool to assess dignity in adreno-cortical tumours. J Clin Endocrinol Metab 1996;81: 4488-4491.
-
(1996)
J Clin Endocrinol Metab
, vol.81
, pp. 4488-4491
-
-
Marx, C.1
Wolkersdorfer, G.W.2
Brown, J.W.3
-
44
-
-
0034947649
-
EGF mutant receptor vIII as a molecular target in cancer therapy
-
Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001;8:83-96.
-
(2001)
Endocr Relat Cancer
, vol.8
, pp. 83-96
-
-
Kuan, C.T.1
Wikstrand, C.J.2
Bigner, D.D.3
-
45
-
-
45149110737
-
Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine
-
Quinkler M, Hahner S, Wortmann S, et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 2008;93: 2057-2062.
-
(2008)
J Clin Endocrinol Metab
, vol.93
, pp. 2057-2062
-
-
Quinkler, M.1
Hahner, S.2
Wortmann, S.3
-
46
-
-
65749120532
-
New targets and therapeutic approaches for endocrine malignancies
-
Fassnacht M, Kreissl MC, Weismann D, et al. New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther 2009;123: 117-141.
-
(2009)
Pharmacol Ther
, vol.123
, pp. 117-141
-
-
Fassnacht, M.1
Kreissl, M.C.2
Weismann, D.3
-
47
-
-
59449084843
-
Limited prognostic value of the 2004 UICC staging classification for adrenocortical carcinoma-proposal for a revised TNM classification
-
Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 UICC staging classification for adrenocortical carcinoma-proposal for a revised TNM classification. Cancer 2009; 115:243-250.
-
(2009)
Cancer
, vol.115
, pp. 243-250
-
-
Fassnacht, M.1
Johanssen, S.2
Quinkler, M.3
|